Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is a leading healthcare company specializing in radiopharmaceuticals, with a core focus on developing, manufacturing, and distributing advanced diagnostic and therapeutic medical products. Its portfolio features precision imaging agents and diagnostic tools such as Pylarify, Definity, TechneLite, Cardiolite, Neurolite, and Xenon Xe-133 Gas, which are integral in fields like oncology, urology, nuclear medicine, cardiology, and radiology. The company also has an active pipeline, including candidates targeting neuroendocrine tumors and Alzheimer’s disease, reflecting ongoing innovation and research commitment. Lantheus Holdings caters to a diverse client base of hospitals, diagnostic testing facilities, and clinics globally, supporting clinicians in detecting and managing diseases such as cancer and cardiovascular conditions. With its global presence and strategic industry partnerships, Lantheus Holdings plays a significant role in driving advancements in medical imaging and targeted diagnostics, underlining its importance in the broader healthcare technology sector.